Citadel Advisors
FBRX icon

Citadel Advisors’s Forte Biosciences FBRX Stock Holding History

Citadel Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.04M Buy
+233,369
New +$6.72M ﹤0.01% 4031
2025
Q4 		– Sell
-15,633
Closed -$234K – 13056
2025
Q3 		$234K Buy
+15,633
New +$180K ﹤0.01% 10888
2024
Q3 		– Sell
-324
Closed -$4.35K – 14498
2024
Q2 		$4.35K Sell
324
-805
-71% -$13K ﹤0.01% 13494
2024
Q1 		$19.8K Buy
1,129
+784
+227% +$13.7K ﹤0.01% 13022
2023
Q4 		$7.08K Buy
+345
New +$4.82K ﹤0.01% 13314
2023
Q3 		– Sell
-900
Closed -$19.9K – 14524
2023
Q2 		$23.4K Buy
900
+897
+29,900% +$23.3K ﹤0.01% 12597
2023
Q1 		$68 Sell
3
-180
-98% -$4.53K ﹤0.01% 14601
2022
Q4 		$4.57K Buy
+183
New +$4.69K ﹤0.01% 14084
2022
Q3 		– Sell
-3,255
Closed -$103K – 12896
2022
Q2 		$106K Sell
3,255
-6,014
-65% -$191K ﹤0.01% 11357
2022
Q1 		$338K Sell
9,269
-679
-7% -$25.7K ﹤0.01% 10319
2021
Q4 		$533K Buy
9,948
+7,858
+376% +$529K ﹤0.01% 9546
2021
Q3 		$155K Buy
2,090
+1,696
+430% +$940K ﹤0.01% 12341
2021
Q2 		$331K Sell
394
-4,214
-91% -$3.8M ﹤0.01% 11031
2021
Q1 		$3.95M Sell
4,608
-9,822
-68% -$8.04M ﹤0.01% 4791
2020
Q4 		$13.1M Buy
14,430
+805
+6% +$757K ﹤0.01% 2291
2020
Q3 		$16.5M Buy
+13,625
New +$9.03M ﹤0.01% 1743
2020
Q2 		– Sell
-123
Closed -$56K – 9983
2020
Q1 		$56K Buy
+123
New +$48.1K ﹤0.01% 8972
2019
Q4 		– Sell
-206
Closed -$51K – 9291
2019
Q3 		$51K Sell
206
-73
-26% -$111K ﹤0.01% 8696
2019
Q2 		$700K Buy
+279
New +$827K ﹤0.01% 6282
2019
Q1 		– Sell
-61
Closed -$236K – 9437
2018
Q4 		$186K Buy
61
+18
+42% +$77.5K ﹤0.01% 7922
2018
Q3 		$251K Buy
+43
New +$164K ﹤0.01% 7863

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Citadel Advisors's FBRX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Forte Biosciences (FBRX) in Q1 2026: 233,369 shares worth $6.04M. The stake represents ﹤0.01% of the portfolio and ranks #4031 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in FBRX as recently as Q3 2025.

Citadel Advisors first reported a position in FBRX in Q3 2018 and has held it in 21 quarters since. The position peaked at $16.5M in Q3 2020. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Citadel Advisors held 233,369 shares of Forte Biosciences worth $6.04M as of Q1 2026.
  • Forte Biosciences was a new Citadel Advisors position in Q1 2026.
  • Forte Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4031 holding.
  • Citadel Advisors first reported a position in Forte Biosciences in Q3 2018 and has held it in 21 quarters since.
  • Citadel Advisors's Forte Biosciences position peaked at $16.5M in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.